Home › Funds › Harold Davidson & Associates Inc. › ALLO
Harold Davidson & Associates Inc. position in ALLO
ALLOGENE THERAPEUTICS INC · Health Care
Harold Davidson & Associates Inc. reported holding 281,434 shares of ALLO (ALLOGENE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$450K, representing 0.18% of its reported portfolio and ranking #47 among its reported holdings. Harold Davidson & Associates Inc. has disclosed ALLO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-10-30 · Source: SEC EDGAR Form 13F-HR
How Harold Davidson & Associates Inc.'s ALLO position evolved
Harold Davidson & Associates Inc. first disclosed a stake in ALLO in Q4 2024 at 232,615 shares (US$495K). The position peaked in Q1 2026 at 289,222 shares, worth US$706K. Across 8 filings, Harold Davidson & Associates Inc. increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 281,434 shares valued at US$450K. Notable position changes include a 46% trim in Q2 2025 (shares rose 10% over the following quarter), a 118% increase in Q3 2025 (shares rose 10% over the following quarter), a 49% increase in Q1 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 232.62K | $495.47K | New |
| Q1 2025 | 252.35K | $368.43K | Add |
| Q2 2025 | 135.23K | $152.81K | Reduce |
| Q3 2025 | 295.43K | $366.34K | Add |
| Q4 2025 | 194.75K | $266.81K | Reduce |
| Q1 2026 | 289.22K | $705.70K | Add |
| Q2 2026 | 281.52K | $585.57K | Reduce |
| Q3 2026 | 281.43K | $450.29K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALLO and 13F data
ALLO (ALLOGENE THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ALLO — the largest reported positions include PFIZER INC (US$46.9M), Frazier Life Sciences Management, L.P. (US$46.7M), TPG GP A, LLC (US$38.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALLO
- PFIZER INC 22.03M sh · $46.93M · Q2 2026
- Frazier Life Sciences Management, L.P. 22.45M sh · $46.69M · Q2 2026
- TPG GP A, LLC 18.72M sh · $38.93M · Q2 2026
- Sio Capital Management, LLC 13.32M sh · $27.71M · Q2 2026
- GordonMD Global Investments LP 5.30M sh · $11.02M · Q2 2026
- Patient Square Capital LP 5.05M sh · $10.50M · Q2 2026
- Wildcat Capital Management, LLC 2.92M sh · $6.08M · Q2 2026
- DAFNA Capital Management LLC 2.00M sh · $4.16M · Q2 2026
More on Harold Davidson & Associates Inc.
FAQ
How long has Harold Davidson & Associates Inc. held ALLO?
Harold Davidson & Associates Inc. has disclosed ALLO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Harold Davidson & Associates Inc.'s current position in ALLO?
As of Q3 2026, Harold Davidson & Associates Inc. holds 281.43K shares of ALLO (ALLOGENE THERAPEUTICS INC), valued at $450.29K, representing 0.18% of its reported portfolio and ranking #47.
Has Harold Davidson & Associates Inc. been buying or selling ALLO?
In the latest 13F filing (Q3 2026), Harold Davidson & Associates Inc. held unchanged its position in ALLO. The position peaked in Q1 2026 at 289.22K shares.
Which other funds hold ALLO?
Other major institutional holders of ALLO include PFIZER INC, Frazier Life Sciences Management, L.P., TPG GP A, LLC, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.